MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
18.50
+1.47
+8.63%
After Hours: 18.52 +0.02 +0.11% 19:56 02/06 EST
OPEN
17.59
PREV CLOSE
17.03
HIGH
18.64
LOW
17.51
VOLUME
3.17M
TURNOVER
--
52 WEEK HIGH
120.05
52 WEEK LOW
10.42
MARKET CAP
1.94B
P/E (TTM)
-5.8037
1D
5D
1M
3M
1Y
5Y
1D
Average Software Stock Now Down Since Tariff Tantrum Lows
Seeking Alpha · 1d ago
Arrowhead   Pharmaceuticals  misses Q1 revenue estimates
Reuters · 1d ago
Is Sarepta (SRPT) Quietly Redefining Its Rare Disease Strategy With a Huntington’s Trial Bet?
Simply Wall St · 1d ago
BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm 
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-CDW, Destiny Tech100, Avery Dennison
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Bio-Techne, AbbVie, Johnson Controls
Reuters · 2d ago
Sarepta receives approval to start SRP-1005 trial in New Zealand
TipRanks · 3d ago
BUZZ-Sarepta rises on NZ regulatory nod to start Huntington's disease trial
Reuters · 3d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.